XTX Topco Ltd Takes Position in Tyra Biosciences, Inc. $TYRA

XTX Topco Ltd purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,601 shares of the company’s stock, valued at approximately $331,000. XTX Topco Ltd owned 0.07% of Tyra Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Tyra Biosciences in the 1st quarter worth $84,000. US Bancorp DE raised its holdings in shares of Tyra Biosciences by 50.5% in the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after acquiring an additional 1,823 shares in the last quarter. Swiss National Bank lifted its stake in Tyra Biosciences by 42.0% in the first quarter. Swiss National Bank now owns 29,400 shares of the company’s stock worth $273,000 after acquiring an additional 8,700 shares during the period. Nuveen LLC purchased a new stake in Tyra Biosciences in the first quarter worth about $465,000. Finally, American Century Companies Inc. grew its holdings in Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after acquiring an additional 1,289 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TYRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, August 22nd. Raymond James Financial started coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Tyra Biosciences Stock Down 2.8%

Shares of TYRA opened at $21.50 on Friday. The company has a 50 day moving average of $16.31 and a two-hundred day moving average of $12.74. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $22.83. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -11.50 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.50). On average, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the sale, the director owned 3,833,425 shares of the company’s stock, valued at approximately $77,626,856.25. This trade represents a 6.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 15.20% of the company’s stock.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.